Status:
COMPLETED
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Lead Sponsor:
Nycomed
Conditions:
Cancer
Pain
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Primary Objective: To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients. Secondary Objective: To explore the relationship between the re...
Eligibility Criteria
Inclusion
- Has the patient given informed consent according to local requirements before any trial-related activities? Trial-related activities are any procedures that would not have been performed during the routine management of the patient.
- Is the patient a cancer patient with breakthrough pain?
- Is the patient aged ≥ 18 years?
- Has the patient received, for at least the past month, either oral morphine, oxycodone, hydromorphone, or transdermal fentanyl for treatment of background pain?
- Is the current dose of the scheduled background pain opioid of the patient equivalent to 60-500 mg oral morphine/day or to 25-200 µg/hour transdermal fentanyl?
- Is the background pain generally stable and on average controlled to a mild level (defined as ≤ 4 on an 11-point numerical rating scale \[NRS\]) by the background pain opioid?
- Is the BTP(s) in general of such severe pain intensity that the patient judges he/she needs additional analgesics (apart from background pain medication) and does it normally last for more than 15 minutes?
- Does the patient, in general, while using a stable fixed-schedule opioid regimen have at least three BTP episodes per week but no more than four BTP episodes per day?
- Has the patient obtained at least partial relief of BTP(s) with his/her usual immediate-release strong opioid, i.e. oral morphine, oxycodone, hydromorphone or transmucosal fentanyl?
- Is the life expectancy of the patient at least 3 months?
- Is the patient able to use intranasal drugs?
- Does the patient use adequate contraceptive precautions (contraceptive pill, implant or injection, or intrauterine device) in the trial period?
- Does the patient have a negative pregnancy test?
- Was the background pain, during a minimum of five of the seven days, controlled to a mild level (defined as ≤ 4 on an 11-point NRS) by the background pain opioid?
- Did the patient have at least three BTP episodes during the seven days but no more than four BTP episodes per day?
- Was the BTP(s) of such severe pain intensity that the patient took additional analgesics (apart from the usual background pain opioid)?
Exclusion
- Does the patient have a recent history of substance abuse?
- Is the patient pregnant or nursing during the trial period?
- Does the patient have neurological or psychiatric impairment that may compromise data collection?
- Does the patient have severe hepatic impairment? (Investigator's judgement according to local practice.)
- Has the patient had any recent therapy, which could potentially alter pain or response to analgesics to a degree, where the need for background pain opioid will be:
- less than 60 mg morphine or morphine equivalents/day; or
- less than 25 µg/hour transdermal fentanyl or the number of BTP episodes will be less than three per week during the trial period?
- Has the patient had facial radiotherapy?
- Has the patient been treated with a monoamine oxidase (MAO) inhibitor within the last 14 days?
- Does the patient use methadone or buprenorphine?
- Does the patient have impaired respiratory function to an extent which may severely increase the risk of clinically relevant respiratory depression by BTP fentanyl treatment?
- Does the patient use drugs for intranasal administration?
- Does the patient have a nasopharyngeal probe?
- Is the patient known to be hypersensitive to fentanyl or to other opioids or any of their excipients?
- Does the patient have any head injury, primary brain tumour, or other pathological conditions which could significantly increase the risk of increased intracranial pressure or impaired consciousness?
- Is the patient concomitantly participating in any other trial with an investigational drug or device apart from cancer treatment and participation in NAF trial FT-016-IM within 30 days prior to inclusion in this trial?
- Does the patient have pathological conditions of the nasal cavity as contraindications to intranasal fentanyl?
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00345735
Start Date
May 1 2006
End Date
October 1 2007
Last Update
May 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed
Roskilde, Denmark, 4000